| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $0 | 0 | 0 |
Sells | $39,345 | 5 | 100 |
| Baluch Khoso | director | 0 | $0 | 1 | $2,588 | $-2,588 |
| Hare Joshua | Chief Scientific Officer | 0 | $0 | 1 | $7,367 | $-7,367 |
| Soffer Rock | director | 0 | $0 | 3 | $29,390 | $-29,390 |
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Over the last 12 months, insiders at Longeveron Inc. have bought $0 and sold $39,345 worth of Longeveron Inc. stock.
On average, over the past 5 years, insiders at Longeveron Inc. have bought $665,157 and sold $513,142 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 42,553 shares for transaction amount of $100,000 was made by Hare Joshua (Chief Scientific Officer) on 2024‑04‑11.
| 2025-05-30 | Sale | Soffer Rock | director | 11,000 0.0739% | $1.25 | $13,750 | -1.65% | |
| 2025-05-29 | Sale | Soffer Rock | director | 10,000 0.0661% | $1.30 | $13,000 | -3.09% | |
| 2025-05-22 | Sale | Soffer Rock | director | 2,000 0.0128% | $1.32 | $2,640 | -4.81% | |
| 2025-05-16 | Sale | Hare Joshua | Chief Scientific Officer | 5,250 0.0346% | $1.40 | $7,367 | -7.84% | |
| 2024-12-02 | Sale | Baluch Khoso | director | 1,250 0.0084% | $2.07 | $2,588 | -24.27% | |
| 2024-04-11 | Hare Joshua | Chief Scientific Officer | 42,553 1.9683% | $2.35 | $100,000 | -8.91% | ||
| 2024-04-11 | Soffer Rock | director | 31,915 1.4762% | $2.35 | $75,000 | -8.91% | ||
| 2024-04-11 | Hashad Mohamed Wa'el Ahmed | Chief Executive Officer | 10,638 0.4921% | $2.35 | $24,999 | -8.91% | ||
| 2024-04-10 | Hare Joshua | Chief Scientific Officer | 106,383 4.4178% | $2.35 | $250,000 | -17.78% | ||
| 2024-04-10 | Soffer Rock | director | 106,383 4.4178% | $2.35 | $250,000 | -17.78% | ||
| 2024-01-10 | Ross Cathy | director | 5,000 0.0205% | $1.31 | $6,545 | -83.67% | ||
| 2023-12-29 | Baluch Khoso | director | 8,322 0.0349% | $1.43 | $11,915 | -84.15% | ||
| 2023-12-28 | PFEFFER JEFFREY | director | 10,000 0.0392% | $1.35 | $13,500 | -84.46% | ||
| 2023-12-28 | Baluch Khoso | director | 1,678 0.0068% | $1.40 | $2,342 | -84.46% | ||
| 2023-09-12 | Sale | Hashad Mohamed Wa'el Ahmed | Chief Executive Officer | 13,405 0.0782% | $3.00 | $40,215 | -80.84% | |
| 2023-09-12 | Locklear Lisa | Chief Financial Officer | 5,000 0.0292% | $3.00 | $15,000 | -80.84% | ||
| 2023-09-08 | Sale | Hare Joshua | Chief Scientific Officer | 50,000 0.294% | $3.00 | $150,000 | -78.80% | |
| 2023-09-07 | Sale | Hare Joshua | Chief Scientific Officer | 15,400 0.0906% | $3.00 | $46,200 | -78.71% | |
| 2023-09-06 | Sale | Hare Joshua | Chief Scientific Officer | 17,700 0.1072% | $3.00 | $53,100 | -78.12% | |
| 2023-09-01 | Sale | Hare Joshua | Chief Scientific Officer | 196,510 1.0361% | $3.00 | $589,530 | -80.47% |
| Hare Joshua | Chief Scientific Officer | 721796 4.809% | $873,373.16 | 6 | 11 | +41.18% |
| Soffer Rock | director | 209034 1.3927% | $252,931.14 | 6 | 4 | +36.8% |
| Baluch Khoso | director | 23750 0.1582% | $28,737.50 | 2 | 1 | <0.0001% |
| Soffer Donald M | director | 153514 1.0228% | $185,751.94 | 1 | 0 | <0.0001% |
| Green Geoff | CEO | 139723 0.9309% | $169,064.83 | 1 | 0 | +76.64% |
| Lehr Paul T | General Counsel, Secretary | 116366 0.7753% | $140,802.86 | 1 | 0 | +100.9% |
| Clavijo James | CFO and Treasurer | 47303 0.3152% | $57,236.63 | 1 | 4 | +100.9% |
| Hashad Mohamed Wa'el Ahmed | Chief Executive Officer | 19616 0.1307% | $23,735.36 | 1 | 1 | <0.0001% |
| PFEFFER JEFFREY | director | 15000 0.0999% | $18,150.00 | 1 | 0 | <0.0001% |
| Ross Cathy | director | 10000 0.0666% | $12,100.00 | 1 | 0 | <0.0001% |
| Locklear Lisa | Chief Financial Officer | 5000 0.0333% | $6,050.00 | 1 | 0 | <0.0001% |
$53,490,060 | 55 | 19.35% | $21.07M | |
$6,204,522 | 45 | 1.91% | $21.54M | |
$383,884 | 32 | -25.10% | $17.54M | |
$4,368,362 | 28 | -22.35% | $16.84M | |
Longeveron Inc. (LGVN) | $1,995,470 | 22 | 14.01% | $18.16M |
$555,628 | 21 | 43.52% | $17.15M | |
$112,810,270 | 18 | -1.20% | $16.63M | |
$11,247,055 | 15 | -26.49% | $17.36M | |
$1,199,157 | 14 | 7.52% | $23.23M | |
$105,917 | 11 | -28.06% | $19.92M | |
$456,220 | 9 | 34.12% | $20.24M | |
$189,648 | 9 | -52.20% | $16.53M | |
$5,574,954 | 8 | -0.97% | $21.04M | |
$26,000,000 | 5 | -56.00% | $22.8M | |
$149,611 | 4 | -25.43% | $16.91M | |
$82,917 | 4 | -11.54% | $19.48M | |
$245,940 | 2 | 31.12% | $17.83M | |
$44,529 | 2 | -30.33% | $16.32M | |
$30,190 | 1 | -42.39% | $20.89M |
| Increased Positions | 8 | +26.67% | 83,004 | +17.02% |
| Decreased Positions | 11 | -36.67% | 60,297 | -12.36% |
| New Positions | 2 | New | 2,381 | New |
| Sold Out Positions | 6 | Sold Out | 34,087 | Sold Out |
| Total Postitions | 27 | -10% | 510,471 | +4.66% |
| Vanguard Group Inc | $225.00 | 1.11% | 144,272 | +99,288 | +220.72% | 2024-12-31 |
| Geode Capital Management, Llc | $208.00 | 1.03% | 133,605 | +4,658 | +3.61% | 2024-12-31 |
| State Street Corp | $71.00 | 0.35% | 45,380 | +30,200 | +198.95% | 2024-12-31 |
| Virtu Financial Llc | $47.00 | 0.23% | 30,402 | +30,402 | New | 2024-12-31 |
| Capital Investment Advisory Services, Llc | $41.00 | 0.2% | 26,525 | 0 | 0% | 2025-03-31 |
| Jane Street Group, Llc | $32.00 | 0.16% | 20,493 | +20,493 | New | 2024-12-31 |
| Northern Trust Corp | $28.00 | 0.14% | 18,190 | +18,190 | New | 2024-12-31 |
| Commonwealth Equity Services, Llc | $19.00 | 0.1% | 12,455 | +12,455 | New | 2024-12-31 |
| Hrt Financial Lp | $18.00 | 0.09% | 11,681 | +11,681 | New | 2024-12-31 |
| Blackrock, Inc. | $16.00 | 0.08% | 10,016 | 0 | 0% | 2025-03-31 |